<p><strong>Natural Alternatives International, Inc.</strong>（納斯達克代碼：NAII）的股東們會很高興地看到，股價在過去一個月表現出色，上漲了 35%，並從之前的疲軟中恢復過來。不幸的是，過去一個月的漲幅對過去一年的損失幾乎沒有幫助，股票在此期間仍然下跌了 15%。</p>
<p>即使在如此大幅的價格上漲之後，如果你認為 Natural Alternatives International 是一隻具有良好投資前景的股票，考慮到美國個人產品行業中幾乎一半的公司市銷率（&#34;P/S&#34;）超過 1 倍，市銷率為 0.2 倍也是可以理解的。然而，我們需要更深入地探討，以確定是否有合理的依據來解釋較低的市銷率。</p>
<p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
<p>查看我們對 Natural Alternatives International 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/290602-ps-multiple-vs-industry-1-dark-2/1764067484400?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/290602-ps-multiple-vs-industry-1-dark-2/1764067484400"/></p>
<p>納斯達克 GM:NAII 市銷率與行業比較 2025 年 11 月 25 日</p>
<h3>Natural Alternatives International 的表現如何</h3>
<p>最近，Natural Alternatives International 的收入穩步上升，這令人欣慰。也許市場預計這種可接受的收入表現將會下滑，這使得市銷率保持在低位。如果你喜歡這家公司，你會希望這種情況不會發生，這樣你就可以在它不受歡迎時買入一些股票。</p>
<p>想要了解公司在收益、收入和現金流方面的全面情況嗎？那麼我們對 Natural Alternatives International 的 <strong>免費</strong> 報告將幫助你揭示其歷史表現。</p>
<h2>收入增長指標告訴我們關於低市銷率的什麼？</h2>
<p>有一個內在的假設，即公司應該表現不及行業，才能使像 Natural Alternatives International 這樣的市銷率被視為合理。</p>
<p>回顧一下，我們看到公司去年收入增長了令人印象深刻的 19%。然而，這還不夠，因為最近三年期間，公司總收入經歷了 24% 的大幅下滑。因此，可以公平地説，最近的收入增長對公司來説並不理想。</p>
<p>將這一中期收入軌跡與更廣泛行業一年的 5.0% 的擴張預測進行對比，顯示出這並不樂觀。</p>
<p>根據這些信息，我們並不感到驚訝，Natural Alternatives International 的市銷率低於行業水平。然而，隨着收入的下滑，市銷率是否已經觸底並沒有保證。如果公司不改善其收入增長，市銷率可能會進一步下降。</p>
<h2>最後的結論</h2>
<p>最新的股價飆升不足以將 Natural Alternatives International 的市銷率拉近行業中位數。我們認為，市銷率的作用主要不是作為估值工具，而是用來衡量當前投資者情緒和未來預期。</p>
<p>我們對 Natural Alternatives International 的審查確認，過去中期內公司收入的縮減是其低市銷率的關鍵因素，因為行業預計將會增長。現在，股東們接受低市銷率，因為他們承認未來的收入可能不會帶來任何令人愉快的驚喜。如果最近的中期收入趨勢持續下去，在這種情況下，很難看到股價在短期內有強勁的波動。</p>
<p>你需要注意風險，例如——<strong>Natural Alternatives International 有 3 個警告信號</strong>（還有 1 個讓我們有點不安），我們認為你應該瞭解。</p>
<p>如果這些 <strong>風險讓你重新考慮對 Natural Alternatives International 的看法</strong>，請查看我們互動式的高質量股票列表，以瞭解還有什麼其他選擇。</p>

Natural Alternatives國際

<p>Natural Alternatives International, Inc.（納斯達克代碼：NAII）的股價最近上漲了 35%，從之前的損失中恢復過來。儘管如此，該股票在過去一年中仍然下跌了 15%。公司的市銷率低至 0.2 倍，顯示出投資者的懷疑，因為其收入增長不穩定，去年增長了 19%，但在三年內下降了 24%。行業預測增長為 5%，突顯了 NAII 的表現不佳。投資者持謹慎態度，接受低市銷率是由於未來收入前景的不確定性</p>

<p><strong>Natural Alternatives International, Inc.</strong> (NASDAQ:NAII) shareholders would be excited to see that the share price has had a great month, posting a 35% gain and recovering from prior weakness. Unfortunately, the gains of the last month did little to right the losses of the last year with the stock still down 15% over that time.</p>
<div class="lb-trans"><p><strong>Natural Alternatives International, Inc.</strong>（納斯達克代碼：NAII）的股東們會很高興地看到，股價在過去一個月表現出色，上漲了 35%，並從之前的疲軟中恢復過來。不幸的是，過去一個月的漲幅對過去一年的損失幾乎沒有幫助，股票在此期間仍然下跌了 15%。</p>
</div><p>Even after such a large jump in price, it would still be understandable if you think Natural Alternatives International is a stock with good investment prospects with a price-to-sales ratios (or &#34;P/S&#34;) of 0.2x, considering almost half the companies in the United States' Personal Products industry have P/S ratios above 1x. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.</p>
<div class="lb-trans"><p>即使在如此大幅的價格上漲之後，如果你認為 Natural Alternatives International 是一隻具有良好投資前景的股票，考慮到美國個人產品行業中幾乎一半的公司市銷率（&#34;P/S&#34;）超過 1 倍，市銷率為 0.2 倍也是可以理解的。然而，我們需要更深入地探討，以確定是否有合理的依據來解釋較低的市銷率。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
</div><p>See our latest analysis for Natural Alternatives International</p>
<div class="lb-trans"><p>查看我們對 Natural Alternatives International 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/290602-ps-multiple-vs-industry-1-dark-2/1764067484400" alt="" original-src="https://images.simplywall.st/asset/chart/290602-ps-multiple-vs-industry-1-dark-2/1764067484400"/></p>
<p>NasdaqGM:NAII Price to Sales Ratio vs Industry November 25th 2025</p>
<div class="lb-trans"><p>納斯達克 GM:NAII 市銷率與行業比較 2025 年 11 月 25 日</p>
</div><h3>How Natural Alternatives International Has Been Performing</h3>
<div class="lb-trans"><h3>Natural Alternatives International 的表現如何</h3>
</div><p>Revenue has risen firmly for Natural Alternatives International recently, which is pleasing to see. Perhaps the market is expecting this acceptable revenue performance to take a dive, which has kept the P/S suppressed. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.</p>
<div class="lb-trans"><p>最近，Natural Alternatives International 的收入穩步上升，這令人欣慰。也許市場預計這種可接受的收入表現將會下滑，這使得市銷率保持在低位。如果你喜歡這家公司，你會希望這種情況不會發生，這樣你就可以在它不受歡迎時買入一些股票。</p>
</div><p>Want the full picture on earnings, revenue and cash flow for the company? Then our <strong>free</strong> report on Natural Alternatives International will help you shine a light on its historical performance.</p>
<div class="lb-trans"><p>想要了解公司在收益、收入和現金流方面的全面情況嗎？那麼我們對 Natural Alternatives International 的 <strong>免費</strong> 報告將幫助你揭示其歷史表現。</p>
</div><h2>What Are Revenue Growth Metrics Telling Us About The Low P/S?</h2>
<div class="lb-trans"><h2>收入增長指標告訴我們關於低市銷率的什麼？</h2>
</div><p>There's an inherent assumption that a company should underperform the industry for P/S ratios like Natural Alternatives International's to be considered reasonable.</p>
<div class="lb-trans"><p>有一個內在的假設，即公司應該表現不及行業，才能使像 Natural Alternatives International 這樣的市銷率被視為合理。</p>
</div><p>Taking a look back first, we see that the company grew revenue by an impressive 19% last year. However, this wasn't enough as the latest three year period has seen the company endure a nasty 24% drop in revenue in aggregate. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.</p>
<div class="lb-trans"><p>回顧一下，我們看到公司去年收入增長了令人印象深刻的 19%。然而，這還不夠，因為最近三年期間，公司總收入經歷了 24% 的大幅下滑。因此，可以公平地説，最近的收入增長對公司來説並不理想。</p>
</div><p>Weighing that medium-term revenue trajectory against the broader industry's one-year forecast for expansion of 5.0% shows it's an unpleasant look.</p>
<div class="lb-trans"><p>將這一中期收入軌跡與更廣泛行業一年的 5.0% 的擴張預測進行對比，顯示出這並不樂觀。</p>
</div><p>With this information, we are not surprised that Natural Alternatives International is trading at a P/S lower than the industry. Nonetheless, there's no guarantee the P/S has reached a floor yet with revenue going in reverse. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth.</p>
<div class="lb-trans"><p>根據這些信息，我們並不感到驚訝，Natural Alternatives International 的市銷率低於行業水平。然而，隨着收入的下滑，市銷率是否已經觸底並沒有保證。如果公司不改善其收入增長，市銷率可能會進一步下降。</p>
</div><h2>The Final Word</h2>
<div class="lb-trans"><h2>最後的結論</h2>
</div><p>The latest share price surge wasn't enough to lift Natural Alternatives International's P/S close to the industry median. We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.</p>
<div class="lb-trans"><p>最新的股價飆升不足以將 Natural Alternatives International 的市銷率拉近行業中位數。我們認為，市銷率的作用主要不是作為估值工具，而是用來衡量當前投資者情緒和未來預期。</p>
</div><p>Our examination of Natural Alternatives International confirms that the company's shrinking revenue over the past medium-term is a key factor in its low price-to-sales ratio, given the industry is projected to grow. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises either. If recent medium-term revenue trends continue, it's hard to see the share price moving strongly in either direction in the near future under these circumstances.</p>
<div class="lb-trans"><p>我們對 Natural Alternatives International 的審查確認，過去中期內公司收入的縮減是其低市銷率的關鍵因素，因為行業預計將會增長。現在，股東們接受低市銷率，因為他們承認未來的收入可能不會帶來任何令人愉快的驚喜。如果最近的中期收入趨勢持續下去，在這種情況下，很難看到股價在短期內有強勁的波動。</p>
</div><p>You need to take note of risks, for example - <strong>Natural Alternatives International has 3 warning signs</strong> (and 1 which makes us a bit uncomfortable) we think you should know about.</p>
<div class="lb-trans"><p>你需要注意風險，例如——<strong>Natural Alternatives International 有 3 個警告信號</strong>（還有 1 個讓我們有點不安），我們認為你應該瞭解。</p>
</div><p>If these <strong>risks are making you reconsider your opinion on Natural Alternatives International</strong>, explore our interactive list of high quality stocks to get an idea of what else is out there.</p>
<div class="lb-trans"><p>如果這些 <strong>風險讓你重新考慮對 Natural Alternatives International 的看法</strong>，請查看我們互動式的高質量股票列表，以瞭解還有什麼其他選擇。</p>
</div>

Natural Alternatives 國際公司（NASDAQ:NAII）的股價反彈了 35%，但其業務仍然落後於行業水平